ixmyelocel-T: Clinical Trials

7 trials of ixmyelocel-T, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed. 5 Phase 2, 2 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 25Completed 5
Phase 32Completed 2
Phase 11Completed 1

Follow ixmyelocel-T: new trials by email Literature Review of ixmyelocel-T trials Research Report on ixmyelocel-T

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)
ixmyelocel-T, Placebo - Ischemic Dilated Cardiomyopathy (IDCM)
Phase 2CompletedVericel Corporation1142013-02-202021-05-27
Cell Therapy for Craniofacial Bone Defects
Ixmyelocel-T, Autogenous Bone Grafting - Cleft Palate, Trauma
Phase 1 / Phase 2CompletedUniversity of Michigan182012-08-012017-05-04
An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI)
Ixmyelocel-T, Placebo - Critical Limb Ischemia
Phase 3CompletedVericel Corporation412012-02-012021-05-27
Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy
Ixmyelocel-T, Vehicle Control - Dilated Cardiomyopathy
Phase 2CompletedVericel Corporation222009-12-012021-05-27
Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)
Ixmyelocel-T, Standard of Care - Dilated Cardiomyopathy
Phase 2CompletedVericel Corporation402008-09-012021-05-27
Ixmyelocel-T Treatment of Patients With Osteonecrosis of the Femoral Head
Ixmyelocel-T, Standard of Care Only - Osteonecrosis
Phase 3CompletedVericel Corporation112007-09-012019-10-21
Use of Ixmyelocel-T (Formerly Vascular Repair Cells [VRC]) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia
Ixmyelocel-T, Placebo - Peripheral Arterial Disease
Phase 2CompletedVericel Corporation862007-04-012020-05-20

Conditions studied

Cardiomyopathy, Dilated (2)  ·  Chronic Limb-Threatening Ischemia (2)  ·  Peripheral Vascular Diseases (2)  ·  Cleft Palate (1)  ·  Heart Failure (1)  ·  Ischemia (1)  ·  Osteonecrosis (1)  ·  Peripheral Arterial Disease (1)  ·  Wounds and Injuries (1)

Sponsors

Vericel Corporation (6)  ·  University of Michigan (1)

Countries

United States (7)  ·  Canada (1)

Top investigators

Amit Patel, MD (1)  ·  Anthony J Comerota, MD (1)  ·  Darnell Kaigler, DDS, PhD (1)  ·  Marc Hungerford, MD (1)  ·  Timothy Henry, MD (1)

Results publications

PMID 25142002, PMID 21684715, PMID 22453769, PMID 27059887, PMID 35802393